US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

iShares Neuroscience and Healthcare ETF

40.00

+0.47041.19%

Volume:533

Turnover:21.33K

Market Cap:8.00M

PE:- -

High:40.04

Open:40.04

Low:40.00

Close:39.53

52wk High:43.01

52wk Low:24.78

Shares:200.00K

Float Shares:200.00K

Volume Ratio:0.83

T/O Rate:0.27%

Dividend:0.32

Dividend Rate:0.80%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Praxis Precision price target raised to $514 from $400 at Baird

Praxis Precision Medicines, Inc. : Deutsche Bank Raises Target Price to $475 from $374

THOMSON REUTERS

Scholar Rock Holding Corporation : Bmo Raises Target Price to $76 from $70

THOMSON REUTERS

Hong Kong Stocks Update | INSILICO Surges Over 9% as ISM8969/HT-001 Receives NMPA Clinical Trial Approval for Parkinson's Disease Treatment

Xenon Pharmaceuticals Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Definium Therapeutics Q2 Net Loss Widens on Higher Warrant Costs

Canada's Xenon Pharma Q2 Net Loss Widens on Higher Expenses

Xenon Net Loss Widens 30.7% to $110.74 Million in Q2 FY26

Xenon Pharmaceuticals Q2 Net Income USD -110.736 Million Vs. IBES Estimate USD -105.7 Million

Xenon Pharmaceuticals Q2 Operating Expenses USD 123.155 Million

THOMSON REUTERS

Xenon Pharmaceuticals - Anticipates Sufficient Cash to Fund Operations into 2029

THOMSON REUTERS

Xenon Reports Q2 2026 Financial Results and Provides Business Update

THOMSON REUTERS

The Race to Come up with the Next Big Sleep Drug

Analysts Offer Insights on Healthcare Companies: Tenaya Therapeutics (TNYA), Privia Health Group (PRVA) and Praxis Precision Medicines (PRAX)

Praxis Precision Medicines, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Scholar Rock Holding Corporation Reports Results for the Quarter Ended June 30 - Earnings Summary

Praxis Q2 2026 results: $1.4 billion liquidity supports runway into 2028

Scholar Rock Files for up to $200 Million At-the-Market Stock Offering

Praxis Precision Medicines Posts Investor Deck Highlighting Late-Stage CNS Pipeline, Upcoming PDUFA Dates

Praxis Precision Q2 Net Loss Widens on Higher Expenses

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/IBRN/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"IBRN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBRN\",,,,,undefined,":{"symbol":"IBRN","market":"US","secType":"STK","nameCN":"iShares Neuroscience and Healthcare ETF","latestPrice":40.0001,"timestamp":1787673785039,"preClose":39.5297,"halted":0,"volume":533,"delay":0,"changeRate":0.011899913229799493,"floatShares":200000,"shares":200000,"eps":0,"marketStatus":"Trading","change":0.4704,"latestTime":"08-25 12:06:08 EDT","open":40.04,"high":40.04,"low":40.0001,"amount":21327.64855,"amplitude":0.001009,"askPrice":40.21,"askSize":300,"bidPrice":39.94,"bidSize":300,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1787688000000},"marketStatusCode":2,"adr":0,"exchange":"ARCA","adjPreClose":39.5297,"sharesOutstanding":150000,"nav":39.601587,"aum":7920317.4,"dividendRate":0.008027,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":39.45,"preClose":39.5297,"latestTime":"16:10 EDT","volume":6,"amount":237.1782,"timestamp":1787602204712,"change":-0.0797,"changeRate":-0.002016,"amplitude":0},"volumeRatio":0.833656,"impliedVol":0.1031,"impliedVolPercentile":0.6096},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBRN\",,,,,undefined,":{"symbol":"IBRN","floatShares":200000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.833656,"shares":200000,"dividePrice":0.3211,"high":40.04,"amplitude":0.001009,"preClose":39.5297,"low":40.0001,"week52Low":24.78,"pbRate":"--","week52High":43.01,"institutionHeld":0,"latestPrice":40.0001,"eps":0,"divideRate":0.008027,"volume":533,"delay":0,"ttmEps":0,"open":40.04,"prevYearClose":32.3193,"prevWeekClose":39.6482,"prevMonthClose":36.6044,"prevQuarterClose":38.8263,"fiveDayClose":39.7665,"twentyDayClose":37.4412,"sixtyDayClose":35.6957},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IBRN\",params:#limit:5,,,undefined,":[{"date":"2025-12-16","symbol":"IBRN","amount":0.319807,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"iShares Neuroscience and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-19","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-19"},{"date":"2024-12-17","symbol":"IBRN","amount":0.10114,"announcedDate":"2024-12-16","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-17","defaultRemindTime":1734445800000,"name":"iShares Neuroscience and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-20","payableDate":"2024-12-17","currency":"USD","dateTimestamp":1734411600000,"payDate":"2024-12-20"},{"date":"2023-12-20","symbol":"IBRN","amount":0.006303,"announcedDate":"2023-12-19","type":"dividend","market":"US","newRecordDate":"2023-12-21","defaultRemindTime":1703082600000,"name":"iShares Neuroscience and Healthcare ETF","recordDate":"2023-12-27","payableDate":"2023-12-21","currency":"USD","dateTimestamp":1703048400000,"payDate":"2023-12-27"},{"date":"2023-06-07","symbol":"IBRN","amount":0.008241,"announcedDate":"2023-05-12","type":"dividend","market":"US","newRecordDate":"2023-06-08","defaultRemindTime":1686144600000,"name":"iShares Neuroscience and Healthcare ETF","recordDate":"2023-06-13","payableDate":"2023-06-08","currency":"USD","dateTimestamp":1686110400000,"payDate":"2023-06-13"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IBRN\",market:\"US\",,,undefined,":[{"executeDate":"2023-06-07","recordDate":"2023-06-08","paymentDate":"2023-06-13","value":0.008241,"currency":"USD"},{"executeDate":"2023-12-20","recordDate":"2023-12-21","paymentDate":"2023-12-27","value":0.006303,"currency":"USD"},{"executeDate":"2024-12-17","recordDate":"2024-12-17","paymentDate":"2024-12-20","value":0.10114,"currency":"USD"},{"executeDate":"2025-12-16","recordDate":"2025-12-16","paymentDate":"2025-12-19","value":0.319807,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IBRN\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IBRN\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2657643664","title":"Praxis Precision price target raised to $514 from $400 at Baird","url":"https://stock-news.laohu8.com/highlight/detail?id=2657643664","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657643664?lang=en_us&edition=fundamental","pubTime":"2026-08-07 20:01","pubTimestamp":1786104075,"startTime":"0","endTime":"0","summary":"Baird raised the firm’s price target on Praxis Precision (PRAX) to $514 from $400 and keeps an Outperform rating on the shares. The firm updated it...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/praxis-precision-price-target-raised-to-514-from-400-at-baird-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/praxis-precision-price-target-raised-to-514-from-400-at-baird-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BJT1NW94.SGD","IBRN","BK4139","PRAX","IE0002141913.USD","IE0009355771.USD","LU0320765992.SGD","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","LU0889565916.HKD","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657648808","title":"Praxis Precision Medicines, Inc. : Deutsche Bank Raises Target Price to $475 from $374","url":"https://stock-news.laohu8.com/highlight/detail?id=2657648808","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657648808?lang=en_us&edition=fundamental","pubTime":"2026-08-07 19:26","pubTimestamp":1786101999,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nFWN44419L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00BJJMRZ35.SGD","IE0009355771.USD","IBRN","IE00B4R5TH58.HKD","LU0320765992.SGD","IE00BFTCPJ56.SGD","BK4139","IE0002141913.USD","IE00B2B36J28.USD","LU0889565916.HKD","LU0109394709.USD","IE00BJT1NW94.SGD","PRAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657610982","title":"Scholar Rock Holding Corporation : Bmo Raises Target Price to $76 from $70","url":"https://stock-news.laohu8.com/highlight/detail?id=2657610982","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657610982?lang=en_us&edition=fundamental","pubTime":"2026-08-07 19:08","pubTimestamp":1786100892,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nFWN444123:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","THNR","SRRK","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136673857","title":"Hong Kong Stocks Update | INSILICO Surges Over 9% as ISM8969/HT-001 Receives NMPA Clinical Trial Approval for Parkinson's Disease Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=1136673857","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136673857?lang=en_us&edition=fundamental","pubTime":"2026-08-07 14:10","pubTimestamp":1786083017,"startTime":"0","endTime":"0","summary":"Insilico Medicine (03696) surged more than 9%, trading up 8.1% at HK$44.3 as of the latest update, with a turnover of HK$541 million.According to recent news from Insilico's official WeChat account,...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4218","HT","BK1141","BK1612","BK4588","BK4181","IBBQ","IBRN","BK4585","01611","MDTX","PSYK","BMED","BK1167","KCAI","IBBJ","VXUS","03696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657080663","title":"Xenon Pharmaceuticals Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2657080663","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657080663?lang=en_us&edition=fundamental","pubTime":"2026-08-07 05:01","pubTimestamp":1786050101,"startTime":"0","endTime":"0","summary":"Xenon Pharmaceuticals Inc. reports results for the quarter ended June 30 - Earnings SummaryXenon Pharmaceuticals Inc.XENE.OQreported a quarterly adjusted loss of $1.11 per share for the quarter ended ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL8N4433E4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XENE","BK4139","SBIO","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657650957","title":"Definium Therapeutics Q2 Net Loss Widens on Higher Warrant Costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2657650957","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657650957?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:17","pubTimestamp":1786047436,"startTime":"0","endTime":"0","summary":"Definium Therapeutics Q2 net loss widens on higher warrant costsOverviewUS biopharma firm's Q2 net loss widens, driven by higher warrant liabilities and expensesCompany raised $805 mln in public offer","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4431D2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","IE0009355771.USD","DTIL","IE00BJJMRZ35.SGD","LU0109394709.USD","IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","DFTX","IE0002141913.USD","BK4139","LU0889565916.HKD","VTVT","IBRN","PRAX","BK4007","IE00B2B36J28.USD","IE00BJT1NW94.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657650887","title":"Canada's Xenon Pharma Q2 Net Loss Widens on Higher Expenses","url":"https://stock-news.laohu8.com/highlight/detail?id=2657650887","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657650887?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:14","pubTimestamp":1786047240,"startTime":"0","endTime":"0","summary":"Canada's Xenon Pharma Q2 net loss widens on higher expensesOverviewCanada neuroscience drug developer's Q2 net loss widened and missed analyst expectationsHigher R&D and administrative costs drove the","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4431DZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009355771.USD","IE00BJT1NW94.SGD","PRAX","LU0889565916.HKD","LU2065169927.USD","GHRS","LU0320765992.SGD","BK4007","XENE","LU0154245756.USD","IE0002141913.USD","LU2065170008.USD","IE00BJJMRZ35.SGD","LU0823416689.USD","BK4563","LU0154245673.USD","BK4139","BK4539","LU2065171402.SGD","NBIX","LU2324357040.USD","PSIL","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","LU0109394709.USD","LU2065171311.SGD","IBRN","IMRX","SBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657571056","title":"Xenon Net Loss Widens 30.7% to $110.74 Million in Q2 FY26","url":"https://stock-news.laohu8.com/highlight/detail?id=2657571056","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657571056?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:07","pubTimestamp":1786046831,"startTime":"0","endTime":"0","summary":"Xenon net loss widens 30.7% to $110.74 million in Q2 FY26Xenon posted a Q2 net loss of USD 110.7 million, widening from USD 84.7 million a year earlier.R&D costs rose to USD 99.2 million from USD 75 m","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDLbgCR29:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","IBRN","IE00BGHQF748.EUR","IE00BKPKM429.USD","IE00B64PRP62.GBP","SG9999014021.USD","SG9999014013.SGD","LU2210149790.SGD","SBIO","BK4585","BK4139","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","NDAQ","BCDF","IE00BN0W2W23.USD","SG9999014039.USD","XENE","LU2210150020.SGD","BK4588","IE00B3QW5Z07.USD","LU0314104364.USD","LU2095319765.USD","BK4112"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657365271","title":"Xenon Pharmaceuticals Q2 Net Income USD -110.736 Million Vs. IBES Estimate USD -105.7 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657365271","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657365271?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:02","pubTimestamp":1786046521,"startTime":"0","endTime":"0","summary":"BRIEF-Xenon Pharmaceuticals Q2 Net Income USD -110.736 Million Vs. IBES Estimate USD -105.7 MillionAug 06 (Reuters) - Xenon Pharmaceuticals Q2 income from operations USD -123.155 million.Q2 operating expenses USD 123.155 million","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nPLXHL9M8F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRN","SBIO","BK4139","XENE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657652480","title":"Xenon Pharmaceuticals Q2 Operating Expenses USD 123.155 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657652480","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657652480?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:01","pubTimestamp":1786046461,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nPLXHL9M8F:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SBIO","IBRN","XENE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657521606","title":"Xenon Pharmaceuticals - Anticipates Sufficient Cash to Fund Operations into 2029","url":"https://stock-news.laohu8.com/highlight/detail?id=2657521606","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657521606?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:01","pubTimestamp":1786046461,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nPLXHL9M8F:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["XENE","SBIO","IBRN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657465223","title":"Xenon Reports Q2 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2657465223","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657465223?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:01","pubTimestamp":1786046461,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nTUA4YCGCT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SBIO","IBRN","BK4139","XENE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657651052","title":"The Race to Come up with the Next Big Sleep Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2657651052","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657651052?lang=en_us&edition=fundamental","pubTime":"2026-08-07 02:30","pubTimestamp":1786041000,"startTime":"0","endTime":"0","summary":"Narcolepsy isn't easy to treat. Existing drugs manage patients' symptoms -- notably excessive daytime sleepiness and difficulty sleeping at night -- rather than the cause. Yet a new type of drug is em","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0096364046.USD","LU1983299246.USD","LLYZ","SG9999018857.SGD","TAK","IE00B1XK9C88.USD","LU0432979614.USD","LU1804176565.USD","OZEM","LU0079474960.USD","LU0097036916.USD","IE00BJJMRX11.SGD","LU0708995401.HKD","LU2168564495.EUR","SG9999015945.SGD","XLV","LU2552382132.HKD","IE00BJLML261.HKD","LU0354030438.USD","LU2471134952.CNY","LU0889565916.HKD","LU2471134879.HKD","LU0158827781.USD","LU1917777945.USD","LU2168564149.EUR","CURE","LU0964807845.USD","LU0787776722.HKD","LU2111349929.HKD","LU2471134523.USD","THNR","JDOC","IE00BK4W5L77.USD","LU1069344957.HKD","IXJ","LU0640476718.USD","MEDX","LLYX","LU0289739699.SGD","LU0122379950.USD","HRTS","LU0114720955.EUR","LU0316494557.USD","LU2265009873.SGD","IE00BFSS8Q28.SGD","LU2552382215.SGD","LU2357305700.SGD","LLII","BK4581","BK4599","IE00B2B36J28.USD","LU1720051108.HKD","LU2089284900.SGD","LU0820561818.USD","LU2491050071.SGD","FTXH","LU2756315318.SGD","IE00B1BXHZ80.USD","CANC","LU1551013425.SGD","LU0345770308.USD","RXL","SG9999015978.USD","LU0266013472.USD","LU0109394709.USD","LU0094547139.USD","LU0106261372.USD","LU2106854487.HKD","SG9999014906.USD","LU1280957306.USD","IBRN","IYH","ILDR","LU2168564065.EUR","LU0823434740.USD","IE00B7KXQ091.USD","LU2491049909.HKD","LU2461242641.AUD","IE00BJJMRZ35.SGD","LU0320765059.SGD","LU1023059063.AUD","ALKS","LU2237443895.HKD","MHIP","LLY","LU0466842654.USD","LU0943347566.SGD","LU2108987350.USD","SG9999001176.USD","LU1127390331.HKD","PSIL","IE0004445015.USD","BK4585","IE0002141913.USD","IE00BFSS7M15.SGD","IE00BJT1NW94.SGD","LU0225283273.USD","LU0471298777.SGD","LU2271345857.HKD","LU2462591350.SGD","LU2471134796.USD","PPH","LU2023250330.USD","LU1548497426.USD","LU2028103732.USD","FBT","LU0471298694.HKD","LU2213496289.HKD","LU2468319806.SGD","LU2087625088.SGD","BK4533","TRUH","LU1989771016.USD","LU2089283258.USD","LU1712237335.SGD","LU1623119135.USD","LU2491050154.USD","BK4534","LU2063271972.USD","LU0456855351.SGD","IE0004445239.USD","LU1868836757.USD","IE00BK4W5M84.HKD","IE00BN29S564.USD","LU2746668974.SGD","LU0353189680.USD","SG9999015952.SGD","LU2023251221.USD","LU1974910355.USD","LU2756315664.SGD","MEDI","SG9999013999.USD","LU0786609619.USD","LU2361044949.HKD","SG9999014898.SGD","FHLC","LU0238689110.USD","BK4007","LU0256863902.USD","LU0820562030.AUD","LU1868837136.USD","GB00BDT5M118.USD","LU0345770993.USD","LU1988902786.USD","LU2168564222.USD","LU0820561909.HKD","LU1814569148.SGD","LU1057294990.SGD","LU1979441026.SGD","LU1366192091.USD","LU0882574055.USD","LU0210536198.USD","IHE","LU1035775433.USD","LU2237443622.USD","LU0203201768.USD","LU0354030511.USD","SGXZ31699556.SGD","LU1868837300.USD","PSCH","LU2112291526.USD","SG9999018865.SGD","BK4588","LU2602419157.SGD","LU1093756325.SGD","LU2456880835.USD","LU2360106947.USD","AGNG","SG9999001176.SGD","LU0672654240.SGD","LU1267930730.SGD","LU1629891620.HKD","SGXZ51526630.SGD","LU2462157665.USD","LU2750360997.AUD","SGXZ99366536.SGD","LU2089984988.USD","ELIS","LU0882574139.USD","LU1868836914.USD","LU2750360641.GBP","LU2552382058.USD","LU0320765992.SGD","IE00BJJMRY28.SGD","LU2264538146.SGD","IE0009355771.USD","SG9999014880.SGD","IE00BKPKM429.USD","LU0689472784.USD","GDOC","LU1720051017.SGD","SG9999015986.USD","LU0133085943.USD","SGXZ81514606.USD","IE00BKDWB100.SGD","LU2896262040.SGD","LU0353189763.USD","WDNA","BK4139","LU1551013342.USD","LU2237443382.USD","LU1323610961.USD","LU2361045086.USD","LU0058720904.USD","LU0823416689.USD","SGXZ57979304.SGD","IE00BWXC8680.SGD","BK4516","LU0061475181.USD","IE00BFTCPJ56.SGD","LU0203202063.USD","LU2324357040.USD","IE00B4R5TH58.HKD","LU1093756168.USD","LU1145028129.USD","LU1291159041.SGD","LU0109391861.USD","LU2168563687.JPY","LU0385154629.USD","LU2023250504.SGD","LU0234572021.USD","LU2211815571.USD","LU2237443549.SGD","TMED","SG9999017495.SGD","LU2237443465.HKD","LU0323591593.USD","LU1232071149.USD","ELIL","LU0158827948.USD","LU1061106388.HKD","IE0005OL40V9.USD","LU2236285917.USD","LU2361044865.SGD","IE0001KFT4U8.USD","LU1064131342.USD","LU0683600562.USD","PJP","IE00B775H168.HKD","IE00B4JS1V06.HKD","LU1868836591.USD","LU2237438978.USD","LU0823434583.USD","LU2237443978.SGD","SG9999014914.USD","LU2417539215.USD","LU0006306889.USD","LU0256863811.USD","LU0198837287.USD","LU0174119429.USD","LU2746668461.USD","LU0417517546.SGD","VHT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657651400","title":"Analysts Offer Insights on Healthcare Companies: Tenaya Therapeutics (TNYA), Privia Health Group (PRVA) and Praxis Precision Medicines (PRAX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657651400","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657651400?lang=en_us&edition=fundamental","pubTime":"2026-08-07 01:50","pubTimestamp":1786038610,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Tenaya Therapeutics (TNYA), Privia Health Group (PRV...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-tenaya-therapeutics-tnya-privia-health-group-prva-and-praxis-precision-medicines-prax-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-tenaya-therapeutics-tnya-privia-health-group-prva-and-praxis-precision-medicines-prax-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0128526141.USD","HCSG","BK4585","XLV","IE00B2B36J28.USD","IE00BJT1NW94.SGD","LU0029874061.USD","BK4588","BK4196","IE00B4R5TH58.HKD","IE00BJJMRZ35.SGD","LABU","IBRN","BK4581","TNYA","PRVA","IE0002141913.USD","XBI","PRAX","IE00BFTCPJ56.SGD","LU0889565916.HKD","LU0320765992.SGD","LU0109394709.USD","BK4539","IE0009355771.USD","BK4139","BK4137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657163708","title":"Praxis Precision Medicines, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2657163708","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657163708?lang=en_us&edition=fundamental","pubTime":"2026-08-06 22:07","pubTimestamp":1786025274,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines, Inc. reports results for the quarter ended June 30 - Earnings SummaryPraxis Precision Medicines, Inc.PRAX.OQreported a quarterly adjusted loss of $2.87 per share for the qu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL8N44326M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJT1NW94.SGD","IBRN","BK4139","PRAX","IE0002141913.USD","IE0009355771.USD","LU0320765992.SGD","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","LU0889565916.HKD","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657321716","title":"Scholar Rock Holding Corporation Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2657321716","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657321716?lang=en_us&edition=fundamental","pubTime":"2026-08-06 21:31","pubTimestamp":1786023115,"startTime":"0","endTime":"0","summary":"Scholar Rock Holding Corporation reports results for the quarter ended June 30 - Earnings SummaryScholar Rock Holding CorporationSRRK.OQreported a quarterly adjusted loss of 84 cents per share for the","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL8N4431VG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRN","BK4139","SRRK","THNR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657111634","title":"Praxis Q2 2026 results: $1.4 billion liquidity supports runway into 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2657111634","media":"TradingKey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657111634?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:53","pubTimestamp":1786020784,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines’ Q2 2026 results showed a net loss of $83.7 million, up from $71.1 million a year earlier, while diluted loss per share narrowed to $2.87 from $3.31 because the weighted-average share count increased. R&D expense rose to $69.4 million and G&A expense more than doubled to $27.5 million. Cash, cash equivalents and marketable securities totaled approximately $1.4 billion at June 30, supporting operations into 2028 as Praxis prepares for regulatory decisions on relutrigine and ulixacaltamide and advances key epilepsy studies.","market":"sg","thumbnail":"https://resource.tradingkey.com/cdn/images/article/news/stock10.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cdn/images/article/news/stock10.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/news/earnings/262084149-tradingkey","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","IE00BJJMRZ35.SGD","LU0320765992.SGD","LU0889565916.HKD","IE00BFTCPJ56.SGD","IBRN","BK4585","BK4588","IE00BJT1NW94.SGD","BK4139","IE00B2B36J28.USD","IE00B4R5TH58.HKD","IE0002141913.USD","LU0109394709.USD","PRAX","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657863176","title":"Scholar Rock Files for up to $200 Million At-the-Market Stock Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2657863176","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657863176?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:50","pubTimestamp":1786020621,"startTime":"0","endTime":"0","summary":"Scholar Rock files for up to $200 million at-the-market stock offeringScholar Rock launched a refreshed at-the-market equity program to sell up to USD 200 million of common stock through Jefferies.The","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDLMYqCd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IBRN","SRRK","THNR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657696631","title":"Praxis Precision Medicines Posts Investor Deck Highlighting Late-Stage CNS Pipeline, Upcoming PDUFA Dates","url":"https://stock-news.laohu8.com/highlight/detail?id=2657696631","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657696631?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:37","pubTimestamp":1786019853,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines posts investor deck highlighting late-stage CNS pipeline, upcoming PDUFA datesPraxis Precision Medicines highlighted four late-stage CNS programs, citing portfolio peak sale","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL9lM7CK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0002141913.USD","IE00BJJMRZ35.SGD","LU0109394709.USD","LU0889565916.HKD","BK4139","IE00BJT1NW94.SGD","IBRN","IE00B2B36J28.USD","IE0009355771.USD","PRAX","LU0320765992.SGD","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657395516","title":"Praxis Precision Q2 Net Loss Widens on Higher Expenses","url":"https://stock-news.laohu8.com/highlight/detail?id=2657395516","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657395516?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:12","pubTimestamp":1786018371,"startTime":"0","endTime":"0","summary":"Praxis Precision Q2 net loss widens on higher expensesOverviewUS CNS drug developer's Q2 net loss widened yr/yr on higher operating expensesCompany ended Q2 with $1.4 bln in cash and investments, fund","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4430NP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009355771.USD","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","LU0889565916.HKD","IBRN","IE00BJT1NW94.SGD","IE00B4R5TH58.HKD","BK4007","BK4539","PRAX","LU0109394709.USD","HRMY","IE00B2B36J28.USD","LU0320765992.SGD","PSIL","GHRS","VNDA","IE0002141913.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":4,"totalSize":200,"code":"91000000","status":"200"}]}}